Hikma Pharmaceuticals Reports Strong Start to 2025 Despite Legal Challenges, Eyes Continued Growth
Hikma Pharmaceuticals PLC has reported a 6% year-over-year increase in group revenue, with a positive outlook for the remainder of 2025, driven by strong demand across various segments and geographies.
3 minutes to read